SOLICITATION NOTICE
A -- PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Justification & Approval Document
- Notice Date
- 7/5/2018
- Notice Type
- Justification and Approval (J&A)
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N01CN5503-16
- Archive Date
- 8/1/2018
- Point of Contact
- Kelly L Dempsey, Phone: 3018466654, Nicole Belanger, Phone: 301 624 8754
- E-Mail Address
-
kelly.dempsey@nih.gov, belangern@mail.nih.gov
(kelly.dempsey@nih.gov, belangern@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Award Number
- Various
- Award Date
- 7/2/2018
- Description
- Signed Justification & Approval Document Please see attached Justification & Approval for PREVENT Preclinical Drug Development: Preclinical Efficacy and Intermediate Endpoint Biomarkers. This notice replaces an earlier notice dated July 2, 2018.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N01CN5503-16/listing.html)
- Record
- SN04980384-W 20180707/180705230525-08838656b83aa6977918203b40d8f00e (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |